India has the capability to develop its own innovative gene therapy solutions for thalassemia and sickle cell disease

Dr Gaurav Kharya, Founder & Director of Delhi-based startup Cellogen Therapeutics, is working intensively on developing indigenous CAR T cell therapy for blood cancers in India so that the cost of treatment can be brought down. Also working as a Clinical lead at the Centre for Bone Marrow Transplant and Cellular Therapy & Senior consultant- paediatric hematology, oncology and immunology, Apollo Hospitals, New Delhi, Dr Kharya spoke to BioSpectrum about how Cell and Gene therapy is the future of medicine.